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A B S T R A C T
Since aptamers bind their targets with high afﬁnity and speciﬁcity, they are promising alternative ligands
in protein afﬁnity puriﬁcation. As aptamers are chemically synthesized oligonucleotides, they can be
easily produced in large quantities regarding GMP conditions allowing their application in protein
production for therapeutic purposes. Several advantages of aptamers compared to antibodies are
described in general within this paper. Here, an aptamer directed against the human Vascular Endothelial
Growth Factor (VEGF) was used as afﬁnity ligand for establishing a puriﬁcation platform for VEGF in small
scale. The aptamer was covalently immobilized on magnetic beads in a controlled orientation resulting in
a functional active afﬁnity matrix. Target binding was optimized by introduction of spacer molecules and
variation of aptamer density. Further, salt-induced target elution was demonstrated as well as VEGF
puriﬁcation from a complex protein mixture proving the speciﬁcity of protein-aptamer binding.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Afﬁnity separation is a frequently used method in downstream
processing of recombinant proteins for biomedical or pharmaceu-
tical application because it offers a high product quality and purity.
Currently, natural or recombinant afﬁnity ligands from animal or
bacterial source including antibodies, Protein A or heparin are
commonly used as capture molecules linked to the stationary
chromatography phase [6]. However, especially the production of
proteins for therapeutic purposes demands puriﬁcation methods
without any cell-based material to avoid potential contaminations
with endotoxins, viruses or other pathogens associated with these
components. In contrast to antibodies or heparin, aptamers are in
vitro selected and chemically synthesized single-stranded DNA or
RNA oligonucleotides and therefore fulﬁll this requirement.
In 1990, nucleic acid oligomers were ﬁrst time selected in a
process named SELEX (systematic evolution of ligands by
exponential enrichment) by their ability to bind a certain molecule
with high afﬁnity [3,26]. Due to intramolecular interactions
between their nucleobases, these oligonucleotides, named
aptamers, fold into distinct three-dimensional structures which
enable them to recognize and to bind their corresponding target
molecules. Aptamers bind their targets with afﬁnity and speciﬁcity* Corresponding author.
E-mail address: walter@iftc.uni-hannover.de (J.-G. Walter).
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2215-017X/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article uncomparable to those of antibodies making them an attractive
alternative in afﬁnity chromatography [29], sensing applications
[8,14,16,25,27] and also for therapeutic purposes [2]. Furthermore,
aptamers exhibit many advantages over antibodies: They are cheap
in production, have a high thermal stability, can be produced
regarding GMP conditions and offer the potential for regeneration
after denaturation [9,13]. Aptamers can be chemically modiﬁed at
either 30 or 50-terminus enabling a covalent immobilization in a
controlled orientation on the solid phase. This may prevent loss of
aptamer binding activity and aptamer leakage during the
puriﬁcation process [28]. If necessary, it is also possible to
introduce molecular spacers at the aptamers' termini to avoid
interactions with the solid surface that may interfere with the
correct three-dimensional aptamer conformation and in conse-
quence target binding [30]. Aptamer folding is highly inﬂuenced by
surrounding buffer conditions such as pH, ionic strength or
presence of speciﬁc ions. Thus, buffer exchange is an appropriate
strategy not only for aptamer folding but also for unfolding and
therefore target elution as well as aptamer regeneration. Moreover,
during the SELEX process the selection conditions can be adapted
with respect to the application to obtain aptamers with desirable
properties for protein puriﬁcation [9,29].
In 1999, theapplication of aptamer afﬁnity puriﬁcationwas ﬁrstly
reported for an L-selectin-immunoglobulin fusion protein [21]. Over
the past few years, similar methods utilizing DNA aptamers have
been developed for many other proteins, including Taq-polymerase
[19], thyroid transcription factor [17], lysozyme [7] and alsoder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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binding to the human vascular endothelial growth factor (VEGF)
have been selected [1,4,5,10,18,22], there are no reports about
aptamer-based VEGF afﬁnity puriﬁcation, yet. Instead, heparin is
used commonly as afﬁnity ligand for VEGF puriﬁcation.
In this work the VEGF-binding DNA aptamer V7t1 [18] was
covalently coupled to magnetic beads, generating a functionalized
afﬁnity matrix phase for VEGF puriﬁcation (Fig. 1). The aptamer is
directed against the receptor-binding domain of the protein. Since
different VEGF isoforms share a common receptor binding domain,
the aptamer is able to bind the different isoforms which has been
demonstrated for VEGF121 [18]. While this cross-reactivity might
be limiting for diagnostic application of the aptamer, it is not
restrictive for the downstream processing of recombinant proteins.
Oriented immobilization of the aptamer via 30-terminal amino
groups was chosen for maintenance of molecular ﬂexibility and
three-dimensional aptamer folding. Furthermore the aptamer
immobilization was optimized with regard to aptamer density and
the inﬂuence of spacers between aptamer and surface was
investigated. The functionalized magnetic beads were utilized in
protein binding experiments for characterization of VEGF binding.
2. Material and methods
All buffer salts were purchased from Fluka (Switzerland) and
Sigma (Germany) and were of per analysis quality. All solutions
were prepared with deionized water (ARIUM, Sartorius Stedim
Biotech, Germany) and were ﬁltered (0.2 mm) prior to use.
2.1. Aptamers
All DNA oligonucleotides were purchased from IDT Integrated
DNA Technologies BVBA, Belgium. The following DNA sequences
were used:
V7t1: 50-TGT GGG GGT GGA CGG GCC GGG TAG A-30
V7t1_14B: 50-TGT GGG GGT GGA CGG GCC GGG TAG ATA GTA
TGT GCA ATC-30
V7t1_14T: 50-TGT GGG GGT GGA CGG GCC GGG TAG ATT TTT TTT
TTT TTT-30
V7t1_12EG: 50-TGT GGG GGT GGA CGG GCC GGG TAG A/
dodecaethylene glycol/-30Fig. 1. Principle of protein puriﬁcation processRandom DNA: 50-AAA CCG CGT CTC TAC GAC CGG TGC TCG ATT
TAA TTT CGC TGA CGT GA-30
The sequences of VEGF binding aptamers V7t1 and V7t1_14B
were taken from literature [18]. V7t1_14B corresponds to the
minimal aptamer V7t1 which is 30-terminal elongated with
14 bases of the originally selected aptamer Vap7. V7t1_14T accords
to the V7t1 sequence elongated with 14 thymine nucleotides at 30-
terminus and V7t1_12EG accords to the V7t1 sequence expanded
with a dodecaethylene glycol spacer at 30-terminus. The spacer
length of 14B, 14T and 12EG are estimated to be 5.29 nm, 7.28 nm
and 4.58 nm, respectively (calculation available in the supporting
information). The random DNA oligonucleotide used as negative
control is a randomized oligonucleotide sequence with statistical
base distribution. Oligonucleotides used for immobilization carry a
30 terminal amino group, those for electrophoresis mobility shift
assay and microscale electrophoresis experiments are labeled with
cyanine 3 (Cy3) at the 30-terminus.
2.2. Proteins
Bovine serum albumin (BSA), a-chymotrypsin and myoglobin
were obtained from Sigma–Aldrich GmbH, Germany. Human
VEGF165 was produced as fusion protein with an N-terminal His-
tag. Gene sequence coding for the mature VEGF (amino acids 27-
191 according to Acc. No.: AAA35789) was cloned into pET16b
plasmid (Merck KG, Germany) and afterwards brought into E. coli
BL21(DE3). Cultivation was performed in 2 L bafﬂed shake ﬂasks at
37 C and 150 rpm using terriﬁc broth medium (12 g/L tryptone,
24 g/L yeast extract, 4 mL/L glycerol, 100 mL/L potassium phos-
phate buffer) supplemented with 100 mg/mL carbenicillin. For
main-cultivation, 500 mL medium were inoculated with E. coli cell
suspension to a starting OD600 of 0.05. At OD600 0.5 protein
expression was induced with 1 mM IPTG before the culture was
grown for at least further four hours at 37 C. Protocols for isolation
and resolubilization of inclusion bodies (IB) were developed on the
basis of procedures described in the literature [20,24]). Cells were
harvested by centrifugation (6000 g, 4 C, 15 min), resuspended in
lysis buffer (50 mM Tris/HCl, 1 mM EDTA, 1% Triton X-100, 10 mM
MgCl2, 10 mg/mL DNase II, pH 8), incubated at 20 C for 30 min and
disrupted by ultra-sonication (Labsonic M, Sartorius AG, Germany;
parameters: 3  30 s at 70% amplitude and 0.6 s cycle). Lysates using aptamer-modiﬁed magnetic beads.
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10 mM 2-mercaptoethanol, 2 mM EDTA, 5% glycerol, 0.05% sodium
deoxycholate, 1% Nonidet P-40, pH 8) and centrifuged at 6000  g
and 4 C for 60 min. The insoluble protein pellet was resuspended
in denaturing solubilization buffer (10 mM CHES,1 M urea, 100 mM
L-arginine, 15 mM L-cysteine, 2 mM DTT, 0.05% Tween 20, pH 9.8)
and cell debris was removed by centrifugation (6000  g, 4 C,
120 min). VEGF was puriﬁed by Ni-IMAC chromatography using
HisTrap FF chromatography column (GE Healthcare Europe GmbH,
Germany) and 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl,
300 mM NaCl, 0.05% Tween 20, pH 8 as binding buffer. VEGF was
eluted by addition of 250 mM imidazole. To separate the correct
refolded VEGF, heparin afﬁnity chromatography (HiTrap Heparin
HP column; GE Healthcare Europe GmbH, Germany) was
performed using 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl,
138 mM NaCl, 0.05% Tween 20, pH 8 as binding buffer. The VEGF
containing elution fractions of the Ni-IMAC were pooled and
diluted with two volumes of heparin binding buffer. VEGF was
eluted by addition of 800 mM NaCl. Afterwards, buffer exchange to
V7t1 binding buffer (10 mM Tris/HCl, 100 mM NaCl, 0.05 mM EDTA,
50 mM KCl, 0.05% Tween 20 pH 7.0) was performed via
ultraﬁltration using Vivaspin 10 kDa centrifugal concentrators
(Sartorius AG, Germany). Puriﬁed proteins were stored at 4 C.
2.3. Electrophoresis mobility shift assay
For electrophoresis mobility shift assay, 40 pmol of Cy3-labeled
V7t1 aptamer were incubated with 300 pmol VEGF, myoglobin,
BSA or a-chymotrypsin in V7t1 binding buffer for 30 min at 4 C,
respectively. Samples were mixed with an equal volume of loading
buffer (20 mM Tris/HCl, 10% glycerol, 0.02% bromophenol blue, pH
6.8) and separated via electrophoresis utilizing a 1.5% agarose gel
and 25 mM Tris/HCl, 50 mM glycine, pH 9.5 as running buffer. DNA-
bands were visualized with a gel documentation system (Ge iX
Imager, Intas, Germany).Fig. 2. Characterization of aptamer target binding via microscale thermophoresis and ele
VEGF. Cy3-labeled V7t1 was incubated with different concentrations of VEGF and aft
75.9 nM  13.0 nM was determined for this interaction. Right: analysis of aptamer bi
a-chymotrypsin (Chy) and bovine serum albumin (BSA) via EMSA. The Cy3-labeled ap
samples were analyzed by agarose gel electrophoresis. Pure VEGF and V7t1 were used as n
V7t1 to VEGF in comparison to the other tested proteins.2.4. Microscale thermophoresis
Microscale thermophoresis experiments were kindly enabled
by NanoTemper Technologies GmbH (Germany). A ﬁnal concen-
tration of 50 nM Cy3-labeled aptamer V7t1 was incubated with a
two-fold dilution series of VEGF in a ﬁnal concentration range of
1250–0.61 nM for 10 min at 4 C in V7t1 binding buffer. Afterwards,
each sample was loaded into a glass capillary (K004 hydrophilic
capillaries) and was subsequently analyzed by Monolith
NT.115 MST system (NanoTemper Technologies GmbH, Germany)
at 90% LED power and 20% MST. The KD-value was calculated from
triplicate experiments by non-linear curve ﬁtting based on the law
of mass action with KD as single free parameter.
2.5. Characterization of nonspeciﬁc VEGF-binding to different surface
materials
For characterization of nonspeciﬁc VEGF binding to different
surface materials three types of magnetic beads were used:
polystyrene beads (Dynabeads M-270Carboxyl, Life Technologies
Inc., CA, USA), silane beads (BioMag Carboxyl, Polysciences Inc., PA,
USA) and agarose beads (NHS Mag Sepharose, GE Healthcare
Europe GmbH, Germany). In order to block reactive groups of the
magnetic beads, 1.5 mg of polystyrene and silane beads or 100 mL
of agarose bead suspension were coupled with Tris according to the
manufacturers’ instructions, respectively. Afterwards, the beads
were washed three times with V7t1 binding buffer and incubated
with 100 mL puriﬁed VEGF (200 mg/mL, corresponding to 4.4 nM)
in V7t1 binding buffer for one hour at 4 C. The beads were washed
three times with 100 mL V7t1 binding buffer and were ﬁnally
resuspended in 50 mL V7t1 binding buffer. All fractions, including
the magnetic beads were incubated with SDS sample buffer
(275 mM sodium dodecyl sulfate (SDS), 500 mM DTT, 30% glycerol,
50% 2-mercaptoethanol) for 10 min at 95 C and subsequently
analyzed by SDS-PAGE analysis utilizing a 16% polyacrylamid gel
under denaturing conditions. SDS-PAGE gels were either silverctrophoresis mobility shift assay (EMSA). Left: saturation curve of V7t1 aptamer and
erwards analyzed by microscale thermophoresis as three-fold replicates. A KD of
nding to the target protein VEGF and the non-target proteins myoglobin (Myo),
tamer V7t1 was incubated with an excess of protein, respectively. Afterwards the
egative controls, respectively. Results of the EMSA demonstrate a speciﬁc binding of
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Breeze Chromogenic Immunodetection Kit (Life Technologies Inc.,
CA, USA) and anti VEGF antibody (Abgent, #AJ1813). PageRuler
Unstained Protein Ladder and PageRuler Plus Prestained Protein
Ladder (Thermo Scientiﬁc, MA, USA) were used as molecular
weight markers.
2.6. Aptamer immobilization
Aptamers were immobilized to tosyl-activated polystyrene
magnetic beads (Dynabeads M-280 Tosyl, Life Technologies Inc.,
CA, USA) in a EDC-free coupling reaction. Amino-modiﬁed oligonu-
cleotides were diluted in 100 mM sodium borate buffer (SBB), pH
9.5 to a ﬁnal concentration in a range between 1 and 50 mM. 1.2 mg
magnetic beads were washed three times with 100 mM SBB, pH
9.5 using a magnetic stand for bead separation. Afterwards, the
buffer was removed and 100 mL of oligonucleotide solution were
added. After short mixing, 70 mL of ammonium sulfate solution (3 M
in 100 mM SBB, pH 9.5) were added. Coupling was performed under
rotation overnight at 37 C. The supernatant was removed and
100 mL blocking buffer (50 mM Tris in 100 mM SBB pH 9.5) were
added for blocking the uncoupled tosyl groups. Blocking was
performed under rotation for three hours at 37 C. The supernatant
was removed, the beads were washed three times with bead wash
buffer (50 mM Tris/HCl, 300 mM NaCl, 0.05% Tween 20, pH 7) and
additionally three times with V7t1 binding buffer. Aptamer
concentrations in the initial solutions, supernatants and washing
fractions were determined with a NanoDropTM 1000 spectropho-
tometer (Thermo Scientiﬁc, MA, USA) and Lambert–Beer equation
utilizing the associated extinction coefﬁcients. The amount of bound
aptamer and the immobilization efﬁciency were calculated by
subtraction of the aptamer amount in the supernatants and washing
fractions from that in the initial solution.
2.7. Characterization of VEGF-binding to aptamer-modiﬁed magnetic
beads
Polystyrene magnetic beads modiﬁed with V7t1 aptamer in a
density of 230 pmol/mg were used for characterization of VEGF
binding. Beads were washed three times for 5 min with 100 mLFig. 3. SDS-PAGE analysis of VEGF adsorption to magnetic beads and western blot analys
silver staining: (M) molecular weight marker; (V) initial VEGF-sample; (S) supernatant 
from the magnetic beads by boiling them in SDS sample buffer (bead fraction). VEGF (27 k
magnetic beads. Right: the initial VEGF-sample was analyzed by western blot and 
approximately 26 kDa and 54 kDa were veriﬁed to be VEGF.V7t1 binding buffer, heated for 5 min to 95 C and afterwards
cooled to room temperature to achieve proper aptamer folding. In
total, 250 pmol immobilized aptamer (1.1 mg beads) were incu-
bated with 90 mL VEGF (300 mg/mL; 6.7 mM) at 4 C for 1 h. The
beads were washed three times for 5 min with 100 mL V7t1 binding
buffer and were ﬁnally resuspended in 50 mL V7t1 binding buffer.
All fractions, including the magnetic beads were analyzed by SDS-
PAGE as described above.
2.8. Comparison of aptamer spacers
Different aptamer variants (V7t1, V7t1_14B, V7t_14T,
V7t1_12EG, Random DNA) were immobilized to polystyrene
magnetic beads as described above in a density of approximately
230 pmol/mg. Beads were washed three times for 5 min with
100 mL V7t1 binding buffer, were heated for 5 min to 95 C and
afterwards cooled to room temperature. In total, 235 pmol
immobilized aptamer (0.9–1.1 mg beads) were incubated with
85 mL VEGF (300 mg/mL; 6.7 mM) at 4 C for 1 h. The beads were
washed three times for 5 min at 4 C with 100 mL V7t1 binding
buffer and afterwards three times for 5 min at 4 C with 50 mL
V7t1 elution buffer (V7t1 binding buffer + 500 mM NaCl). VEGF
concentration of all fractions as well as in the initial sample was
analyzed by VEGF ELISA (Thermo Scientiﬁc, #EH2VEGF) according
to the manufacturer’s instructions and the absolute amount of
bound and eluted VEGF was calculated for each aptamer variant.
2.9. Optimization of aptamer density
Polystyrene magnetic beads conjugated with V7t1_14B
aptamer in different densities between 50 and 500 pmol/mg were
washed three times for 5 min with 100 mL V7t1 binding buffer.
They were heated for 5 min to 95 C and afterwards cooled to room
temperature. In total, 270 pmol immobilized aptamer (0.55–
4.75 mg beads) were incubated with 100 mL VEGF (250 mg/mL;
5.6 mM) at 4 C for 1 h. Beads were washed three times for 5 min at
4 C with 100 mL V7t1 binding buffer. VEGF concentration in all
fractions as well as the initial sample was analyzed by VEGF ELISA
(Thermo Scientiﬁc, #EH2VEGF) and the absolute amount of bound
VEGF was calculated for each immobilization density.is of VEGF. Left: the following samples were applied to the SDS-PAGE and stained by
after incubation with magnetic beads; (W3) last washing fraction; (B) VEGF eluted
Da band) adsorbed toTris-blocked silane and agarose particles but not to polystyrene
chromogenic immunodetection utilizing an anti-VEGF antibody. Two bands at
Fig. 4. SDS-PAGE analysis of VEGF adsorption to magnetic beads. The following
samples were applied to the SDS-PAGE and stained by silver staining: (M) molecular
weight marker; (V) initial VEGF-sample; (S) supernatant after incubation with
magnetic beads; (W3, W5) washing fractions; (B) VEGF eluted from the magnetic
beads by boiling them in SDS sample buffer (bead fraction). VEGF (27 kDa band)
binds to V7t1 aptamer which was immobilized on polystyrene magnetic beads.
Fig. 5. Immobilization of V7t1_14B on tosyl-activated magnetic beads. Different
initial aptamer concentrations were applied to the immobilization process resulting
in different aptamer densities on the beads’ surfaces. Furthermore, the immobili-
zation efﬁciency as a function of initial aptamer concentration is presented.
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For creating a complex protein mixture, fetal calf serum was
diluted in V7t1 binding buffer to a total protein concentration of
1 mg/mL and supplemented with VEGF (200 mg/mL). V7t1_14B
and Random DNA modiﬁed polystyrene magnetic beads were
heated to 95 C for 5 min and subsequently cooled to room
temperature. The magnetic beads were incubated with 100 mL
protein mixture in V7t1 binding buffer at 4 C for 1 h. Afterwards,
the beads were washed three times for 5 min at 4 C with 100 mL
V7t1 binding buffer. VEGF was eluted by incubating three times
with 50 mL V7t1 elution buffer. All fractions, including the
magnetic beads were analyzed by SDS-PAGE followed by silver
staining and densitometric analysis using AlphaEaseFC image
analysis software.
3. Results
3.1. Investigation of aptamer-target-binding
Utilization of aptamers in downstream processing requires
their immobilization for example by covalent attachment using a
terminal amino linker. Since aptamer modiﬁcation may result in
misfolding and thus reduced binding afﬁnity, we ﬁrst investigated
binding of the Cy3-labeled aptamer V7t1 to the target protein
VEGF. For determination of the binding afﬁnity, V7t1 was
incubated with different concentrations of VEGF and analyzed
by microscale thermophoresis. Based on the resultant saturation
curve (Fig. 2, left) a KD-value of 75.9 nM  13.0 nM was calculated.Table 1
Effect of aptamer spacers on the VEGF binding capacity and target elution. Aptamer V7t1 
of app. 230 pmol/mg beads, respectively and afterwards incubated with VEGF. The follow
nucleotides spacer (14T spacer) and an additional sequence of 14 deﬁned nucleotides 
Spacer Aptamer density (pmol/mg) Spacer length (
No spacer 230 – 
12EG spacer 247 4.58 
14T spacer 211 7.28 
14B spacer 231 5.29 
Random DNA 207 – In comparison to the KD-value of 1.4 nM, that has been published
for the unmodiﬁed aptamer V7t1 [18], this may indicate a
diminished VEGF binding but may also be a consequence of
different methods used for the determination of the KD (MST
versus SPR). Nevertheless, the binding afﬁnity in a low nanomolar
range is adequate for the application of protein puriﬁcation.
For demonstration of target binding speciﬁcity and investiga-
tion of unspeciﬁc binding to other proteins based on electrostatic
interactions, different aptamer–protein mixtures were analyzed by
electrophoresis mobility shift assay (EMSA). The Cy3-labeled
aptamer V7t1 was incubated with VEGF and with three non-target
proteins offering different isoelectric points (pI), respectively: BSA
(pI 4.7), myoglobin (pI 7.2) and a-chymotrypsin (pI 8.8). The
protein–V7t1-mixtures were analyzed by agarose gel electropho-
resis as well as pure VEGF and V7t1 as negative controls. The
unbound aptamers are able to penetrate the gel, whereas the
proteins and protein–aptamer complexes remain near to the
loading pocket (Fig. 2, right). Two bands were found for the
unbound V7t1 aptamer, indicating a variable three dimensional
aptamer folding which has been described previously by the group
of Plavec [15]. The EMSA conﬁrms the formation of a VEGF-V7t1-
complex (Fig. 2, right, lane 3) in contrast to V7t1 incubated with
myoglobin, a-chymotrypsin or BSA (lanes 4, 5, 6). Here, the bands
appear at the same height as the one of the free aptamer V7t1 (lane
2), indicating no binding between these proteins and the V7t1 even
though the a-chymotrypsin has a basic isoelectric point and is
consequently positively charged under assay conditions (pH 7).
Nonetheless, there is no unspeciﬁc electrostatic binding to the
negatively charged oligonucleotide backbone. Therefore, the
results prove that protein binding is mediated by speciﬁc afﬁnity
recognition rather than electrostatic interactions.with different spacer modiﬁcations was immobilized on magnetic beads in a density
ing spacers were analyzed: dodeca-ethyleneglycol spacer (12EG spacer), 14 thymine
originating from the full length aptamer Vap7 (14B spacer).
nm) Bound VEGF (pmol/mg) Eluted VEGF (pmol/mg)
96.06 82.84
103.23 81.40
175.37 151.14
244.85 226.78
35.17 30.29
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3.2.1. Choice of a suitable surface for aptamer immobilization
For the development of aptamer-based afﬁnity puriﬁcation,
aptamer immobilization on a solid stationary phase is a prerequi-
site. Covalent binding of amino-modiﬁed aptamers to carboxyl-
functionalized surfaces can be mediated by EDC or achieved by
direct coupling to preactivated surfaces e.g. by tosyl- or N-
hydroxysuccinimid (NHS) groups. For VEGF puriﬁcation, function-
alized magnetic beads were used as solid stationary phase
material. As the VEGF tends to adsorb to solid surfaces, we
primarily analyzed VEGF binding to unmodiﬁed magnetic beads. In
order to minimize unspeciﬁc binding towards the stationary phase,
three types of carboxyl-functionalized magnetic beads were
compared, consisting of different surface materials: polystyrene
(carboxyl-functionalized), silane (carboxyl-functionalized) and
agarose (NHS-activated carboxyl group). Functional groups on
the magnetic beads’ surfaces were blocked with Tris to avoid
electrostatic interactions and the magnetic beads were incubated
with puriﬁed VEGF in V7t1 binding buffer. SDS-PAGE analysis
(Fig. 3, left) revealed strong bands of approximately 26 kDa
(around the predicted size of monomeric VEGF) and weak bands of
approximately 54 kDa (around the predicted size of dimeric VEGF)
that were veriﬁed to be VEGF by western blot analysis (Fig. 3,
right). Protein incubation experiments demonstrate a strong
adsorption of VEGF to silane and agarose magnetic beads, as
there remained no VEGF in the supernatant after protein
incubation (lane S), whereas VEGF was eluted from the magnetic
beads by boiling them in SDS sample buffer (lane B). Silane and
agarose both possess hydrophilic surfaces offering multiple
hydroxyl groups which may interact as hydrogen bond donators
with carbonyl or amino groups of the VEGF. In contrast, no binding
to hydrophobic polystyrene particles was observed, as hydropho-
bic interactions between the surface and VEGF could be prohibited
by Tween 20 which is a component of the binding buffer. The
results indicate the particular suitability of polystyrene matrices
for VEGF puriﬁcation. Therefore, they were chosen as stationary
phase for further experiments.
3.2.2. Binding of VEGF to aptamer-modiﬁed magnetic beads
Demonstrating the principle of aptamer-based puriﬁcation,
VEGF binding to aptamer-modiﬁed magnetic beads was investi-
gated. Therefore, the aptamer V7t1 was immobilized on polysty-
rene particles. In total, 250 pmol immobilized aptamer V7t1 were
incubated with an excess of VEGF (600 pmol) in V7t1 bindingFig. 6. Analysis of VEGF binding capacity as a function of aptamer density. V7t1_14B
modiﬁed magnetic beads with different aptamer densities were incubated with
VEGF. The amount of bound VEGF and the percentage of aptamer which has bound a
VEGF-molecule (aptamer activity) were calculated.buffer. SDS-PAGE analysis reveals a VEGF band in the supernatant
obtained after incubation with aptamer-modiﬁed magnetic beads
(Fig. 4, lane S), no bands in the washing fractions (lanes W3, W5),
but a VEGF band after boiling the magnetic beads in SDS sample
buffer (bead fraction, lane B). Thus, VEGF was bound by the
aptamer V7t1 proving that despite of aptamer immobilization
correct aptamer folding is still possible and as a result speciﬁc
target binding is achieved
3.2.3. Introduction of aptamer spacers
Aptamer folding into deﬁned three-dimensional conformations
depends on the molecular ﬂexibility which may be restricted by
aptamer immobilization. The forced contiguousness of the
aptamer to the surface and to other aptamer molecules leads to
intermolecular interactions which may disturb aptamer folding
leading to inhibition of target recognition. Steric hindrance can be
prohibited by introducing spacer molecules between aptamer and
surface [28,30]. The molecular spacers work like ﬂexible arms
which enlarge the distance between aptamer and surface and
hence, support aptamer folding.
To study the inﬂuence of molecular spacers, V7t1 variants
modiﬁed with different types of spacer molecules at the 30-
terminus were immobilized on polystyrene magnetic beads and
their VEGF binding capacities were compared with those of
V7t1 without any spacer and a random DNA sequence. A 36-atom
dodeca-ethyleneglycol spacer (12EG spacer), an aptamer sequence
that was elongated with 14 thymine nucleotides (14T spacer) and
the V7t1 precursor sequence which contains 14 additional bases of
the original selected aptamer Vap7 (14B spacer) were used. All
aptamers were immobilized in a density of approximately
230 pmol per mg beads. Table 1 presents the amount of bound
and eluted VEGF in this binding assay. All V7t1 aptamer variants
were able to bind at least 96 pmol VEGF per mg magnetic beads,
whereas the random DNA sequence bound less than 40 pmol VEGF.
The introduction of a molecular spacer raised the VEGF binding
capacity up to approximately 245 pmol per mg beads. However,
not all types of spacers enhanced VEGF binding. Adding a dodeca-
ethyleneglycol spacer to the V7t1 barely raises the VEGF binding
capacity (1.1 times) whereas aptamer elongation with 14B spacer
increases it up to 2.5 times. The 14B spacer provides a theoretic
distance of 5.29 nm between aptamer and bead surface which is
marginally longer than the distance spanned by the 12EG-spacer
(4.58 nm). The 14T spacer is estimated to be the longest spacer
molecule (7.28 nm) but enhances VEGF binding capacity only
1.8 times. Even though additional room leads to a higher molecular
ﬂexibility this effect does not seem to improve target binding
signiﬁcantly. Rather, neighbored nucleobases support the target
binding, presumably by facilitating the target-induced aptamer
folding as already described for microarray application [12]. Thus,
the V7t1 aptamer with 14B spacer which contains additional bases
of the originally selected aptamer Vap7 is best suited for VEGF
binding. Our results suggest that these bases may additionally
contribute to either target binding or stabilization of aptamer
folding.
Moreover, quantiﬁcation of VEGF in the elution fractions
demonstrates a successful VEGF elution by addition of 500 mM
NaCl to the binding buffer. The ions may interfere with either
intermolecular electrostatic interactions between aptamer and
protein or with intramolecular interactions between the aptamer’s
nucleobases resulting in destabilization of aptamer folding. Salt-
dependent protein elution is a mild elution strategy which may
avoid protein denaturation [23]. For all aptamer variants it was
possible to elute at least 75% of the bound protein which is a
promising basis for VEGF puriﬁcation. Further, sodium chloride can
be easily removed from the immobilized aptamers by thoroughly
Fig. 7. SDS-PAGE analysis of VEGF puriﬁcation from a complex protein mixture.
(A) A mixture of VEGF and FCS in V7t1 binding buffer was incubated with V7t1_14B- and random DNA-modiﬁed magnetic beads. VEGF bound to V7t1_14B but not to the
random DNA. The following samples were applied to the SDS-PAGE and stained by silver staining: (M) molecular weight marker; (P) initial protein sample; (S) supernatant
after incubation with magnetic beads; (W1, W3) washing fractions; (E1, E2) elution fractions; (B) VEGF eluted from the magnetic beads by boiling them in SDS sample buffer
(bead fraction).
(B) VEGF was puriﬁed from solubilized VEGF inclusion bodies, diluted in V7t1 binding buffer using V7t1_14B- modiﬁed magnetic beads.
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beads is possible.
3.2.4. Optimization of aptamer density
Aptamer density on the magnetic beads’ surfaces determines
their maximum target binding capacity. However, a high aptamer
density may also lead to steric hindrance and therefore inhibited
target binding due to interactions between neighbored aptamers.
For investigating the optimal aptamer density, the aptamer
V7t1_14B was immobilized on the magnetic beads in different
densities and VEGF binding capacity was compared. Regulation of
aptamer density was achieved by variation of aptamer concentra-
tion in the immobilization reaction mixture and therefore
variation of the aptamer-to-magnetic bead ratio (Fig. 5). Depend-
ing on the initial aptamer concentration, different immobilization
efﬁciencies were achieved. Immobilization efﬁciency was maximal
(75%) at low initial aptamer concentration of 2 mM and decreases
to 18% with raising initial aptamer concentration. Concurrently,
aptamer densities were in a range between 90 and 740 pmol per
mg.
For investigation of VEGF binding capacity, magnetic beads
with different densities of V7t1_14B were incubated with VEGF
and the amount of bound VEGF was compared. Fig. 6 presents the
analysis of VEGF binding capacity as a function of aptamer density.
Further, the percentage of aptamer which has bound a VEGF
molecule is shown as aptamer activity. Maximum aptamer activity
(81%) was achieved at an aptamer density of 55 pmol per mg beads.
With increasing aptamer density the aptamer activity decreases to
36%. Thus, high aptamer densities seem to impair VEGF binding
which can be a consequence of either inhibited aptamer folding or
a restricted accessibility of immobilized aptamers. Nevertheless,
the amount of bound VEGF per mg beads increases with raising
aptamer density in a non-linear manner up to nearly 180 pmol per
mg beads for an aptamer density of 493 pmol per mg beads. For
optimal VEGF puriﬁcation a low aptamer density of approximately
100 pmol per mg is recommended, as in this case at least 75% of the
aptamer are functionally active. Further, due to the high
immobilization efﬁciency of approximately 73% at these concen-
trations, using a low aptamer density allows a more cost-efﬁcientbead preparation leading to an economic puriﬁcation process.
Therefore, using polystyrene magnetic beads and the aptamer
V7t1_14B immobilized in a density of approximately 100 pmol per
mg beads is recommended for VEGF puriﬁcation.
3.3. VEGF puriﬁcation from a complex protein mixture
Based on the optimized parameters for VEGF binding, we
investigated VEGF puriﬁcation from a complex protein mixture
imitating a protein rich cell lysate fraction consisting of FCS (1 mg/
mL) and VEGF (200 mg/mL). Aptamer-modiﬁed magnetic beads
were incubated with the protein mixture, beads were washed with
V7t1 binding buffer and ﬁnally VEGF was eluted by addition of
500 mM NaCl. SDS-PAGE analysis demonstrates a successful
puriﬁcation of VEGF without any visible contaminations
(Fig. 7A). The purity was estimated to be 91% by densitometry.
Most of the bound VEGF was eluted under the elected elution
conditions (500 mM NaCl), Only a small amount VEGF remained on
the magnetic beads which could be eluted by boiling them in SDS
sample buffer (lane B). In contrast, no unspeciﬁc binding towards
the random DNA-modiﬁed beads was observed.
To prove the applicability of the aptamer-based VEGF puriﬁca-
tion to the E. coli protein extract, solubilized inclusion bodies were
diluted with equal volume of V7t1 binding buffer and afterwards
VEGF puriﬁcation was performed as described above (Fig. 7B). The
purity estimated by densitometry was 91% and therefore is
comparable to the purity achieved by combination of Ni-IMAC and
Heparin-Afﬁnity chromatography which was about 93%.
4. Conclusions
A new aptamer-based afﬁnity puriﬁcation platform for the
Vascular Endothelial Growth Factor was developed and optimized
in a small scale by utilizing magnetic beads. The aptamer V7t1 was
covalently immobilized on polystyrene magnetic beads in a
controlled orientation resulting in a functionally active stationary
afﬁnity matrix which concomitantly exhibits low unspeciﬁc
binding. The aptamers’ binding activity was optimized by
diminishing the aptamer density and by introducing a spacer
M. Lönne et al. / Biotechnology Reports 8 (2015) 16–23 23molecule which consists of 14 additional nucleotides. The platform
permits target elution by enhanced ionic strength due to NaCl
addition. Those mild elution conditions prevent protein denatur-
ation and facilitate a high protein recovery of at least 75%. In
summary, this work demonstrates that the aptamer V7t1 is a
promising alternative to heparin for VEGF afﬁnity puriﬁcation.
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